Biocon's conosldidated net profit surged 154.24% to Rs 344.50 crore in Q4 FY25, compared with Rs 135.50 crore in Q4 FY24.

As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent ...

Liraglutide injection is a GLP-1 receptor agonist used to improve glycemic control in adults and pediatric patients with type 2 diabetes More than 38 million people live with diabetes in the U.S.1 ...

is pleased to announce the expansion of its VSDHOne platform with the launch of Liraglutide. This addition marks a strategic expansion of Hydreight’s growing GLP-1 weight management and wellness ...